Andera Partners said today that it led a $20 million Series D financing round for urology-focused medical device maker Rivermark Medical. Rivermark Medical aims to redefine the treatment of benign prostatic hyperplasia (BPH) through its FloStent platform. It also picked up funding in the Series D from existing investors and an unnamed strategic … [Read more...] about Rivermark Medical brings in $20M to support FloStent device for BPH
